<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age/><report-id>PHHY2013DE006809</report-id><gender>female</gender><reactions><reaction>Renal agenesis congenital on the right side</reaction><reaction>Renal hypoplasia on the left side</reaction><reaction>Consecutive high grade lung hypoplasia on both sides</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>LEPONEX</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>PAROXETINE</drug-name><manufacturer/><ingredients/></drug></drugs><outcomes><outcome>Congenital Anomaly BirthDefect</outcome></outcomes><country>Germany</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149692_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152632</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2013DE006809</safetyreportid>
		<primarysourcecountry>DE</primarysourcecountry>
		<occurcountry>DE</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>2</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>1</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2013-01-22</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-22</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2013DE006809</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<linkedreport>
			<linkreportnumb>PHHY2013DE006768</linkreportnumb>
		</linkedreport>
		<linkedreport>
			<linkreportnumb>PHHY2013DE006768</linkreportnumb>
		</linkedreport>
		<linkedreport>
			<linkreportnumb>de-embryotox-201110001</linkreportnumb>
		</linkedreport>
		<linkedreport>
			<linkreportnumb>de-bfarm-13003071</linkreportnumb>
		</linkedreport>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>DE</reportercountry>
			<qualification code="1">Physician</qualification>
			<observestudytype>2</observestudytype>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification code="3">Other Health Professional</qualification>
			<observestudytype>2</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<parent>
				<parentage>36</parentage>
				<parentageunit>801</parentageunit>
				<parentlastmenstrualdateformat>102</parentlastmenstrualdateformat>
				<parentlastmenstrualdate>20110918</parentlastmenstrualdate>
				<parentsex>2</parentsex>
			</parent>
			<reaction>
				<primarysourcereaction>Renal agenesis congenital on the right side</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Unilateral renal agenesis</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Renal aplasia</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Renal hypoplasia on the left side</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Renal hypoplasia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Renal hypoplasia</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Consecutive high grade lung hypoplasia on both sides</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Pulmonary hypoplasia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Pulmonary hypoplasia</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<test>
				<testname>Ultrasound antenatal screen</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>LEPONEX</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationnumb>19-758</drugauthorizationnumb>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>400</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>400 mg, QD</drugdosagetext>
				<drugadministrationroute code="064">Transplacental</drugadministrationroute>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>CLOZAPINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pulmonary hypoplasia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pulmonary hypoplasia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal aplasia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal aplasia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal hypoplasia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal hypoplasia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>PAROXETINE</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>40</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>40 mg, QD</drugdosagetext>
				<drugadministrationroute code="064">Transplacental</drugadministrationroute>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PAROXETINE HYDROCHLORIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pulmonary hypoplasia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pulmonary hypoplasia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal aplasia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal aplasia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal hypoplasia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal hypoplasia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2013DE006809, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>PMS report from a <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>(<Semaphore x="2305971" class="Occupation" value="Neurologist" score="1.00" ID="C17721">neurologist</Semaphore>) on 22 Jan 2013 via Health Authorities (BfArM 13003071 / de embryotox 201110001). This report refers to a 36-year old female patientâ€™s <Semaphore x="1409585" class="AnatomicStructure" value="Abortus" score="1.00" ID="C73436">aborted fetus</Semaphore>. Mother's medical history included no previous <Semaphore x="3201094" class="MedDRA LLT" value="Pregnancy" score="1.00" ID="10036556">pregnancies</Semaphore>, BMI (<Semaphore x="2820532" class="MedDRA LLT" value="Body mass index" score="1.00" ID="10005894"><Semaphore x="1610517" class="AnatomicStructure" value="Body" score="1.00" ID="C13041">body </Semaphore><Semaphore x="2201019" class="Disease or Finding" value="Mass" score="1.00" ID="C34808">mass </Semaphore>index</Semaphore>) 24.49, no alcohol, nicotin or illicit <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drugs </Semaphore>use. Concomitant medications of the mother included Folsaeure (<Semaphore x="596508" class="Medicine" value="Folic Acid" score="0.49" ID="268863">folic acid</Semaphore>) from an unspecified date for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore><Semaphore x="3206844" class="MedDRA LLT" value="Prophylaxis of neural tube defect" score="1.00" ID="10054930">of <Semaphore x="3206844" class="MedDRA LLT" value="Prophylaxis of neural tube defect" score="1.00" ID="10054930"><Semaphore x="2420563" class="Procedure" value="Preventive Intervention" score="1.00" ID="C15843">prophylaxis </Semaphore>of <Semaphore x="2302675" class="Disease or Finding" value="Neural Tube Defect" score="1.00" ID="C84923">neural tube defect </Semaphore></Semaphore></Semaphore>at an unspecified <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">oral </Semaphore>dose. She was taking <Semaphore x="985426" class="Medicine" value="Paroxetine" score="0.97" ID="253784">paroxetine </Semaphore>(unknown <Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer</Semaphore>) at an <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">oral </Semaphore>dose of 40mg per day for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of schizophrenic <Semaphore x="1855439" class="Disease or Finding" value="Disfigurement" score="1.00" ID="C50536">disorder</Semaphore>. Mother received Leponex (<Semaphore x="385490" class="Medicine" value="Clozapine" score="0.74" ID="252210">clozapine</Semaphore>) at an <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">oral </Semaphore>dose of 400mg per day for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="3241259" class="MedDRA LLT" value="Schizophrenia" score="1.00" ID="10039626">schizophrenic <Semaphore x="1855439" class="Disease or Finding" value="Disfigurement" score="1.00" ID="C50536">disorder </Semaphore>(<Semaphore x="3241259" class="MedDRA LLT" value="Schizophrenia" score="1.00" ID="10039626">schizophrenic <Semaphore x="2435862" class="Disease or Finding" value="Psychosis" score="1.00" ID="C78576">psychoses</Semaphore></Semaphore></Semaphore>) from 18 Sep 2011. She did not have any diseases and her family history was normal. She became <Semaphore x="3201094" class="MedDRA LLT" value="Pregnancy" score="1.00" ID="10036556">pregnant </Semaphore>on an unknown date (see case PHHY2013DE006768). <Semaphore x="2099000" class="Disease or Finding" value="Last Menstrual Period" score="1.00" ID="C81257">Last menstrual period </Semaphore>was reported as 18 Sep 2011. On an unspecified date, a prenatal ultrasound revealed a <Semaphore x="1587671" class="Disease or Finding" value="Bilateral Renal Agenesis" score="1.00" ID="C101219">bilateral <Semaphore x="3226024" class="MedDRA LLT" value="Renal aplasia" score="1.00" ID="10064655">renal agenesis </Semaphore></Semaphore>on the <Semaphore x="1932392" class="AnatomicStructure" value="Fetus" score="1.00" ID="C13235">fetus</Semaphore>. <Semaphore x="2859790" class="MedDRA LLT" value="Chromosomal analysis" score="1.00" ID="10008811">Chromosomal analysis </Semaphore>was not performed. Because of this embryopathology<Semaphore x="2051694" class="Disease or Finding" value="Induced Abortion Finding" score="1.00" ID="C50613">, an <Semaphore x="2708440" class="MedDRA LLT" value="Abortion induced" score="1.00" ID="10000220">abortion was induced </Semaphore></Semaphore>in the 20th <Semaphore x="1976468" class="Procedure" value="Gestational Weeks Assessment" score="1.00" ID="C81253">gestational week</Semaphore>. Mother received <Semaphore x="426414" class="Medicine" value="Cytotec" score="0.74" ID="239517">Cytotec </Semaphore>(<Semaphore x="879052" class="Medicine" value="Misoprostol" score="0.49" ID="268068">misoprostol</Semaphore>) on 30 Jan 2012 to <Semaphore x="2708440" class="MedDRA LLT" value="Abortion induced" score="1.00" ID="10000220">induce the abortion </Semaphore>via <Semaphore x="2462376" class="Disease or Finding" value="Reproductive System Finding" score="0.58" ID="C36284">vaginal </Semaphore>route. <Semaphore x="1558453" class="Disease or Finding" value="Autopsy TNM Finding" score="1.00" ID="C48882">Autopsy </Semaphore>was done and confirmed <Semaphore x="2458488" class="Disease or Finding" value="Renal Agenesis" score="1.00" ID="C99041">renal agenesis </Semaphore>on the right and <Semaphore x="3227415" class="MedDRA LLT" value="Renal hypoplasia" score="1.00" ID="10049102">renal hypoplasia </Semaphore>on the left side. Consecutive high <Semaphore x="2027225" class="Procedure" value="Histopathologic Examination" score="1.00" ID="C18190">grade </Semaphore><Semaphore x="2132044" class="AnatomicStructure" value="Lung Tissue" score="1.00" ID="C33024">lung </Semaphore>hypoplasia on both sides was also reported. The reporter commented that <Semaphore x="985426" class="Medicine" value="Paroxetine" score="0.97" ID="253784">Paroxetine </Semaphore>and the <Semaphore x="1995595" class="Procedure" value="Group Therapy" score="1.00" ID="C21042">group </Semaphore>of SSRI <Semaphore x="1532147" class="Procedure" value="Antidepressant Measurement" score="1.00" ID="C74691">antidepressants </Semaphore><Semaphore x="2009057" class="Procedure" value="Health Assessment Prior to Exposure" score="1.00" ID="C88067">were well </Semaphore>documented <Semaphore x="1532147" class="Procedure" value="Antidepressant Measurement" score="1.00" ID="C74691">antidepressants </Semaphore>during <Semaphore x="3201094" class="MedDRA LLT" value="Pregnancy" score="1.00" ID="10036556">pregnancy</Semaphore>. Although plenty of studies of different designs with partial high numbers of exposed <Semaphore x="3201094" class="MedDRA LLT" value="Pregnancy" score="1.00" ID="10036556">pregnancies </Semaphore>had been performed, there was still some uncertainty concerning <Semaphore x="2265745" class="Disease or Finding" value="Negative Patch Test" score="1.00" ID="C35633">negative </Semaphore>effects on <Semaphore x="2418846" class="Disease or Finding" value="Pregnancy Outcome" score="1.00" ID="C90491"><Semaphore x="3201094" class="MedDRA LLT" value="Pregnancy" score="1.00" ID="10036556">pregnancy </Semaphore>outcome</Semaphore>. An increased risk for <Semaphore x="2875138" class="MedDRA LLT" value="Congenital genitourinary abnormality" score="1.00" ID="10062334">urogenital <Semaphore x="1408895" class="Disease or Finding" value="Abnormality of Ventricle" score="1.00" ID="C50448">anomalies </Semaphore></Semaphore>after <Semaphore x="985426" class="Medicine" value="Paroxetine" score="0.97" ID="253784">paroxetine </Semaphore>exposure had not been reported, yet. Causal relationship cannot be excluded, because <Semaphore x="985426" class="Medicine" value="Paroxetine" score="0.97" ID="253784">paroxetine </Semaphore>exposure took <Semaphore x="2440020" class="AnatomicStructure" value="Putamen" score="1.00" ID="C12452">place </Semaphore>during the <Semaphore x="2953976" class="MedDRA LLT" value="First trimester pregnancy" score="1.00" ID="10052395">first trimester of pregnancy</Semaphore>. <Semaphore x="385490" class="Medicine" value="Clozapine" score="0.74" ID="252210">Clozapine </Semaphore>was not expected to increase the risk of <Semaphore x="1806300" class="Disease or Finding" value="Congenital Abnormality" score="1.00" ID="C2849">congenital anomalies</Semaphore>. However, as it was taken during the sensitive period of organogenesis a causal association between the medication and the renal <Semaphore x="1408895" class="Disease or Finding" value="Abnormality of Ventricle" score="1.00" ID="C50448">anomaly </Semaphore>seemed to be possible. In this case the <Semaphore x="2458488" class="Disease or Finding" value="Renal Agenesis" score="1.00" ID="C99041">renal agenesis </Semaphore>could also have occurred by chance or as <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">result </Semaphore>of a <Semaphore x="1971324" class="Disease or Finding" value="Genetic Disorder" score="1.00" ID="C3101">genetic disorder</Semaphore>. The <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="985426" class="Medicine" value="Paroxetine" score="0.97" ID="253784">paroxetine</Semaphore>, Leponex, Folsaure and <Semaphore x="426414" class="Medicine" value="Cytotec" score="0.74" ID="239517">Cytotec </Semaphore>was discontinued on 31 Jan 2012. The <Semaphore x="2352492" class="Disease or Finding" value="Other Finding" score="0.58" ID="C36295">outcome </Semaphore>for the events was not reported. Seriousness of the events was assessed as <Semaphore x="1806300" class="Disease or Finding" value="Congenital Abnormality" score="1.00" ID="C2849">congenital anomaly </Semaphore>by the reporter.</narrativeincludeclinical>
				<sendercomment>MAC for Leponex: As safe use of clozapine in pregnant women has not been fully established, the causality for the reported events is not assessable.

MAC for paroxitine: paroxitine has been taken during organogenesis, hence the causal relationship with events are plausible.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>